Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered an achievement; in this study, median overall survival was 34 months after treatment with enfortumab vedotin (EV) and pembrolizumab (pembro).
City of Hope's Salvador Jaime-Casas, MD, discusses a systematic review of recent trials examining objective response rate and adverse events of antibody-drug conjugate (ADC) combinations in advanced urothelial cancer.
The American Cancer Society's chief scientific officer outlines the group's research agenda, including a new project in prostate cancer.
Positve overall survival data could lead to a label expansion for Pfizer's combination to treat metastatic castration-resistant prostate cancer (mCRPC).
Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
“To error is human, and also to error is in machine learning,” said Debra Patt, MD, PhD, MBA, MPH.
Debra Patt, MD, PhD, MBA, MPH, warns that prior authorization barriers are delaying critical cancer treatments and urges a regulatory fix for Stark Law restrictions on mailing oral oncolytics.
The 5-part plan focuses on issues that have been calling cards for the Community Oncology Alliance (COA) in recent years, which gained traction in the last Congress and show up regularly on lists of the most pressing problems in health care.
World Cancer Day also marks the start of the ‘United by Unique’ campaign, which seeks to highlight how each person’s journey with cancer is unique, even though the patients, caregivers, and health care teams who are touched by cancer are united by shared goals.
Debra Patt, MD, PhD, MBA, MPH, emphasizes advocacy for pharmacy benefit manager (PBM) reform, physician reimbursement, and sustainable policy solutions to improve access to community cancer care.
Amid the uproar over the firing of 18 inspectors general, a report offering a coda to the aducanumab approval episode has been overlooked. It shows the need for reforms of the FDA's accelerated approval process.
A panel discussion during the JPMorgan conference earlier this month examined where oncology drug development is headed, driven in part by advances in diagnostic testing.
The renewal for the ninth straight year includes McKesson's latest measure for resolution of health-related social needs.
DeepScribe's technology aims to free doctors to focus on the patient visit.
Charleston Area Medical Center (AMC) Vandalia Health was among 3 participants in the Association of Cancer Care Centers' Quality Improvement Program for myeloproliferative neoplasms.
Besides Kent Hospital, the Association of Cancer Care Centers worked with Perlmutter Cancer Center at NYU Langone Hospital and Charleston Area Medical Center Vandalia Health in Charleston, West Virginia.
Perlmutter Cancer Center at NYU Langone was 1 of 3 sites to take part in the Association of Cancer Care Centers quality improvement initiative in myeloproliferative neoplasms (MPNs).
If the subcutaneous delivery method gains approval, an advantage daratumumab holds over isatuximab would be removed.
For several years, investigators have been studying combinations that include ruxolitinib, sold as Jakafi, to treat myeloproliferative neoplasms (MPNs).
Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of Hematology Meeting and Exposition. After this article went to press, the company announced its ticker symbol on the Nasdaq will change January 2, 2025.
Prior authorization, PBM reform, and payment for patient navigation were topics of the most popular articles in EBO in 2024.
Articles on myeloproliferative neoplasms (MPNs) covered the debate over how early to use cytoreductive therapies instead of phlebotomy in younger patients with polycythemia vera, the promise of vaccines, and the unmet potential of pegylated interferons.
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
